Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1LG2 | Q9BQ51 | 8/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 8/20 | 0.35 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | CCR4 | P51679 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16617494 | 0.88 | PLCG1 (0.34) | PDCD1LG2CD274PLCG1MEN1KMT2A | |
| SCHEMBL16617001 | 0.78 | ABCB11 (0.35) | PDCD1LG2CD274MEN1KMT2AMAPT | |
| SCHEMBL20719394 | 0.75 | MEN1 (0.36) | PDCD1LG2CD274ALDH1A1MEN1KMT2A | |
| SCHEMBL20718996 | 0.70 | MEN1 (0.34) | MEN1KMT2AMAPTL3MBTL1 | |
| SCHEMBL16617651 | 0.69 | CYP1A2 (0.40) | PDCD1LG2CD274ALDH1A1MEN1KMT2A | |
| SCHEMBL3508448 | 0.68 | CD274 (0.37) | PDCD1LG2CD274ALDH1A1MEN1KMT2A | |
| SCHEMBL20719376 | 0.68 | GAA (0.33) | PDCD1LG2CD274ALDH1A1MEN1KMT2A | |
| SCHEMBL20719146 | 0.67 | L3MBTL1 (0.34) | PDCD1LG2CD274ALDH1A1MEN1KMT2A | |
| SCHEMBL20719699 | 0.67 | KDM4E (0.39) | PDCD1LG2CD274ALDH1A1MEN1KMT2A | |
| SCHEMBL20719250 | 0.66 | TSHR (0.37) | PDCD1LG2CD274MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3055300-B1 | ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR | PFIZER (US) | 2018-03-07 | — | — | EP | disclosed |
| EP-3055300-B1 | ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR | PFIZER (US) | 2018-03-07 | — | — | EP | disclosed |
| EP-3055300-A1 | ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR | Pfizer Inc. (US) | 2016-08-17 | — | — | EP | disclosed |
| US-9278953-B2 | Antagonists of prostaglandin EP3 receptor | PFIZER INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278953-B2 | Antagonists of prostaglandin EP3 receptor | PFIZER INC. (US) | 2016-03-08 | — | — | US | disclosed |
| WO-2015052610-A1 | ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR | PFIZER INC. (US) | 2015-04-16 | — | — | WO | disclosed |
| US-20150099782-A1 | ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR | PFIZER INC. (US) | 2015-04-09 | — | — | US | disclosed |
| US-20150099782-A1 | ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR | PFIZER INC. (US) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099782-A1 | ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR | PTGER3, PTGES3, PTGER2 | PDCD1LG2 3493/4885CD274 3466/4885PLCG1 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.